Results 91 to 100 of about 36,304 (249)

Regulation of Insulin Secretion Through Long‐Chain Fatty Acid Receptors

iNew Medicine, EarlyView.
Stefan Offermanns
wiley   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies

Life
Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis.
Vincenzo Trapanese, Annamaria Dagostino, Maria Resilde Natale, Federica Giofrè, Clara Vatalaro, Melania Melina, Francesca Cosentino, Silvia Sergi, Felice Imoletti, Rocco Spagnuolo, Franco Arturi   +10 more
doaj   +1 more source

Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis

Diabetology & Metabolic Syndrome, 2018
Background No proper data on prognosis and management of type-2 diabetic ST elevation myocardial infarction (STEMI) patients with culprit obstructive lesion and multivessel non obstructive coronary stenosis (Mv-NOCS) exist.
Raffaele Marfella, Celestino Sardu, Maria Luisa Balestrieri, Mario Siniscalchi, Fabio Minicucci, Giuseppe Signoriello, Paolo Calabrò, Ciro Mauro, Gorizio Pieretti, Antonino Coppola, Gianfranco Nicoletti, Maria Rosaria Rizzo, Giuseppe Paolisso, Michelangela Barbieri   +13 more
doaj   +1 more source

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra, Awad, Mohamed E., Eisa, Nada H., Elmansi, Ahmed M., Fulzele, Sadanand, Hamrick, Mark W., Herberg, Samuel, Hill, William D., Hussein, Khaled A., Isales, Carlos M., Kondrikov, Dmitry, McGee-Lawrence, Meghan E., Periyasamy-Thandavan, Sudharsan, Volkman, Brian F.   +13 more
core   +1 more source

Lipotoxicity impairs incretin signalling [PDF]

Diabetologia, 2012
The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced insulin secretion in response to food ingestion in a glucose-dependent manner. This mechanism forms the basis for incretin-based therapies in type 2 diabetes.
openaire   +2 more sources

Is AMP‐activated protein kinase activation a central mechanism of cardio‐metabolic outcomes after metabolic and bariatric surgery?

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity. It usually results in spectacular weight loss, associated with improvements of obesity‐associated comorbidities. The mechanisms underlying these benefits are not fully understood but could involve a postoperative activation of the enzyme 5′ AMP‐activated ...
Adrien Delcour, Nathalie Niederhoffer
wiley   +1 more source

Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]

, 2018
Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J., Petrie, John R., Touyz, Rhian M.   +2 more
core   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

Journal of Nutrition and Metabolism, 2012
In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-
Dominique Xavier Brown, Marc Evans
doaj   +1 more source